Evaluating the impact of volume averaging in pencil beam scanning proton therapy

Authors:
  • SDSree Bash Chandra Debnath
    Sree Bash Chandra Debnath
  • KCKuan-Ling Chen
    Kuan-Ling Chen
  • FSFan-Chi Su
    Fan-Chi Su
  • JXJingzhu Xu
    Jingzhu Xu
  • RRRobabeh Rahimi
    Robabeh Rahimi

Abstract
Background: Pencil beam scanning (PBS) proton therapy delivers therapeutic doses with exceptional precision through its unique spot-by-spot delivery technique. However, the resulting composite dose profiles—dependent on spot size and spacing—introduce volume averaging that complicates accurate dose determination in treatment planning system (TPS), a critical step in beam commissioning. In this study, we aim to quantify the clinical impact of volume averaging in TPS for PBS proton therapy and establish an optimal dose acquisition strategy in TPS to minimize volume averaging effect that facilitates accurate and safe patient treatment. Methods: Treatment plans were designed within RayStation TPS using PBS proton beams of 70, 150 and 225 MeV with spot spacings from 0.18 to 0.6 cm. The plans incorporated a PPC05 parallel-plate (PP) chamber in a virtual water phantom. Dose density, defined as dose per unit area, was introduced to quantify the impact of spot size and spacing on volume averaging. Following beam configuration guidelines in the TPS, the chamber was placed at various depths. Volume doses (Dvtps) were obtained from a contoured volume of the chamber’s active measurement element, and point doses (Dptps) were obtained from dose specification point (DSP) at the inner surface of the chamber’s entrance window along the central axis. Subsequently, the plans were also delivered in a water phantom on an IBA ProteusPlus PBS machine, and the measured doses in the phantom, Dm , were compared with the TPS values of Dptps and Dvtps to assess volume averaging. Results: Significant discrepancies were observed between Dptps and Dvtps at lower dose densities. The maximum deviations occurred at 0.1 cGy·cm−2, where Dptps was higher than Dvtps by +4.5% for 70 MeV, +2.2% for 150 MeV, and +4.3% for 225 MeV. The in-phantom verifications showed similar results. Overall, point doses in TPS showed better agreement with phantom verification than volumetric doses. At vendor-recommended commissioning condition (0.4 cGy·cm−2), all discrepancies fell below ±1%. Conclusions: We recommend using point-based dose acquisitions in TPS to reduce volume averaging in PBS proton therapy. Furthermore, adherence to vendor-recommended commissioning settings in beam configuration minimized the deviations between volumetric and point doses observed in this study.